SLC5A2 and metabolic dysfunction-associated steatohepatitis: In addition, several clinical studies have reported that SGLT2 inhibitors have favorable effects on NAFLD/NASH in patients with type 2 diabetes (Ohta et al., 2017; Scheen, 2019; Yamauchi et al., 2019).